Adrián Dante De Angelis/LinkedIn
Oct 21, 2026, 09:30
Adrián Dante De Angelis: Research That Opens New Possibilities for Recurrent iTTP
Adrián Dante De Angelis, Hematologist at Spital STS AG, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Frontiers in Immunology, adding:
“I am truly happy to be able to share our publication in Frontiers and, above all, to be able to offer new treatment options to this small group of patients with iTTP and multiple relapses.”
Title: Case Report: Zanubrutinib for refractory immune thrombotic thrombocytopenic purpura
Authors: Adrián Dante De Angelis, Annatina Schnegg-Kaufmann, Elisavet Moutzouri, Katarzyna Aleksandra Jalowiec, Milos Ratknic, Johanna A. Kremer Hovinga, Ioannis Chanias
Stay updated with Hemostasis Today.
-
Oct 21, 2026, 09:13Jarod Horobin: Blood 2026 – Connecting Science and People
-
Oct 21, 2026, 08:35Raeeda Gheewala: VTE in Athletes – Risks Beyond the Playing Field
-
Oct 21, 2026, 08:29Andreas Kronbichler: The Changing Landscape of CV Risk in ANCA-Associated Vasculitis
-
Oct 21, 2026, 08:21Pham Quy: Taking Stroke Awareness Beyond Hospitals and Into the Community
-
Oct 21, 2026, 07:15Mahmoud Saad: Successful Mechanical Thrombectomy for Right Atrial Thrombosis
-
Oct 21, 2026, 06:55Hunain Shahbaz: Extended Dual Antiplatelet Therapy Beyond 12 Months After Drug-Eluting Stent Implantation
-
Oct 21, 2026, 06:19Dawood Findakly: When Should Anticoagulation Be Held or Resumed?
-
Oct 21, 2026, 03:36Steve Watson: Ligand Epitope Ratios Influence Antagonist Inhibition
-
Oct 21, 2026, 03:18Stephen D. Coombs: Superficial Venous Thrombosis in Athletes and Importance of Early Recognition and Referral